Also known as Recombinant human growth hormone · rhGH · 191aa HGH · Human growth hormone · Genotropin · Humatrope · Norditropin · Nutropin · Saizen · Omnitrope · Serostim
Recombinant 191-amino-acid human growth hormone — a folded protein biologic identical in sequence to pituitary GH, not a synthetic research peptide.
Somatropin is recombinant human growth hormone (rHGH): a single 191-amino-acid polypeptide, ~22.1 kDa, with the exact sequence of the major form secreted by the human pituitary. Unlike the short synthetic peptides elsewhere in this catalog, it is a folded protein biologic — produced in engineered cells, stabilized by two internal disulfide bonds, and dependent on its three-dimensional structure for activity. It is FDA-approved for several growth-hormone-deficiency and short-stature indications, and is simultaneously one of the most misunderstood molecules in the anti-aging conversation.
Somatropin is a biologic, and that distinction is the point of including it here. The research peptides in this catalog are mostly short chains built by solid-phase synthesis; somatropin is a full 191-residue protein with defined secondary and tertiary structure — a four-helix bundle held by two disulfide bridges (Cys53–Cys165 and Cys182–Cys189). Its sequence is identical to the dominant 22 kDa form of growth hormone the pituitary releases, which is why it is called "recombinant human" growth hormone rather than an analog. Activity lives in the fold: denature the protein and you do not get a weaker peptide, you get an inactive one.
The molecule also carries its own history. Until 1985, growth hormone was extracted from cadaveric pituitaries — a supply that was abruptly halted when several recipients developed Creutzfeldt–Jakob disease from prion contamination. Recombinant production solved both the supply and the safety problem. The first recombinant product (somatrem) carried an extra N-terminal methionine, a 192-amino-acid artifact of bacterial expression; somatropin is the true 191-amino-acid, native-sequence version that followed and now defines the class across brands such as Genotropin, Humatrope, Norditropin, and Saizen.
Mechanistically, growth hormone is a relay, not a direct effector. It binds and dimerizes the GH receptor, triggering JAK2/STAT5 signaling, and much of what people attribute to "GH" is actually the work of IGF-1 produced downstream in the liver. GH does have direct actions — it mobilizes fat and antagonizes insulin — but the growth and anabolic story runs largely through the GH/IGF-1 axis. This is also why the secretagogues elsewhere in this catalog (the GHRH analogs and GHRPs) exist: they coax the pituitary into releasing this same molecule, preserving the body’s pulsatile feedback rather than supplying a flat exogenous dose.
Then there is the drama. In 1990 a small New England Journal of Medicine study by Daniel Rudman gave GH to twelve older men and reported reduced fat and increased lean mass over six months. That single paper — 12 subjects, no functional endpoints — became the founding myth of the GH anti-aging industry. The journal’s own editors later published an unusual note cautioning against using it to justify anti-aging treatment, and subsequent work documented the costs of supraphysiologic GH in healthy adults: fluid retention, carpal tunnel syndrome, joint pain, and insulin resistance. The headline rarely traveled with the footnotes.
The deepest irony is the longevity science. Across model organisms, it is reduced GH/IGF-1 signaling — not elevated — that tracks with extended lifespan: GH-receptor-knockout mice are among the longest-lived strains known, and humans with Laron syndrome (GH-receptor insensitivity) show strikingly low rates of cancer and diabetes. So a hormone marketed for "longevity" sits on an axis whose downregulation is one of the most reproducible pro-longevity signals in biology. That tension — real, FDA-approved medicine for genuine deficiency; oversold and legally restricted as an anti-aging tonic; and pointing the opposite direction from the longevity data — is exactly why it belongs in an honest reference.
Binds a single GH receptor that then dimerizes, activating JAK2/STAT5 signaling. Most anabolic and growth effects are mediated indirectly through hepatic IGF-1 induction; GH also acts directly to drive lipolysis and oppose insulin.
Behind every vial of Somatropin (rHGH) is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Somatropin (rHGH), specifically, is brought into being.
On paper, Somatropin (rHGH) is C990H1528N262O300S7 — about 22,124 daltons of precisely arranged atoms. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Assembling Somatropin (rHGH) means roughly 191 coupling cycles on the synthesizer — one protected residue added at a time, which is also 191 chances for an incomplete coupling to seed a deletion impurity. At this length the growing chain is prone to aggregation on the resin, making every later cycle harder — long sequences are where small per-cycle losses compound into a messy crude. It also carries a disulfide bridge, an extra step beyond a plain chain that adds both capability and cost.
The crude mixture — Somatropin (rHGH) plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one. Somatropin (rHGH) carries 4 cysteines, whose thiols are oxidation-sensitive and can form disulfide links — reactive chemistry that purification has to control rather than ignore. It also contains oxidation-prone methionine or tryptophan residues, another family of impurities the chromatography has to resolve away.
A real batch of Somatropin (rHGH) proves itself: identity confirmed by mass spectrometry against its ~22,124 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Somatropin (rHGH) — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Somatropin is not made by solid-phase peptide synthesis. It is expressed recombinantly — historically in E. coli (often as inclusion bodies requiring refolding) and in mammalian cell lines — then purified by multi-step chromatography and verified for correct folding and disulfide pairing. Identity and potency rest on protein-specific methods (peptide mapping, mass spectrometry, bioassay/cell-based potency, host-cell-protein and endotoxin testing), not an HPLC purity percentage alone. This is the defining difference between a complex biologic hormone and the short synthetic peptides in the rest of this catalog.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning Somatropin, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
Somatropin is recombinant human growth hormone — a 191-amino-acid protein, ~22 kDa, with the same sequence as the growth hormone made by the human pituitary. It is a folded biologic, not a synthetic peptide, and is FDA-approved for several growth-hormone-deficiency and short-stature conditions.
Its activity depends on three-dimensional structure — a four-helix fold stabilized by two disulfide bonds — and it is produced in living cells, not by solid-phase synthesis. That makes its manufacturing, characterization, and quality control much closer to a protein drug than to a short research peptide.
Off-label, yes — that use traces largely to a small 1990 study whose authors and journal later warned against extrapolating it. Healthy-adult use carries documented side effects (edema, carpal tunnel, joint pain, insulin resistance), and U.S. law specifically restricts distributing hGH for uses the FDA has not authorized.
The reverse is better supported in research: lower GH/IGF-1 signaling is associated with longer lifespan in animal models and with reduced cancer and diabetes in people with GH-receptor insensitivity (Laron syndrome). The popular "longevity" framing runs against much of the aging biology.
No. This is a research and educational reference. Somatropin is a prescription biologic with specific approved indications and significant legal restrictions; nothing here is a recommendation to obtain or use it.
The active fragment of parathyroid hormone — a recombinant peptide that builds bone, exploiting a paradox: the same hormone resorbs bone when continuous, but builds it when pulsed.
ViewThe downstream effector of growth hormone — a 70-amino-acid recombinant protein, structurally a cousin of proinsulin, that carries out most of GH’s growth signal.
ViewModified GHRH(1-29) analog with short plasma half-life.
View